NR1I3 and chronic myelogenous leukemia, BCR-ABL1 positive: To the best of our knowledge, this is the first study on the impact of ABCB1, ABCG2, PXR, and CAR gene polymorphisms on the outcomes of dasatinib treatment in CML.